The Environmental Risk Assessment (ERA) play a key role in regulatory submissions for medicines in the European Union. The European Medicines Agency (EMA) requires a clear, evidence-based process to assess the potential environmental impact of active pharmaceutical ingredients (APIs) that enter the environment through patient use. With the updated EMA guideline (EMEA/CHMP/SWP/4447/00 Rev. 1 – EMA […]

